Flash Glucose Monitoring device Freestyle Libre is approved for funding in Norway for the treatment and follow-up of children with diabetes

Norway established in 2013 a framework for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment. This framework is called the “New Method”.

In this framework, all innovations should undergo HTA before being funded. Selection of methods is performed by the Ordering Forum (Bestillerforum). If the method is of national concern, it undergoes Single Technology Appraisal at national level followed by the funding decision by the group of payers (Decision Forum, Beslutningsforum). Decision Forum has regular meetings to review results of assessments to the make funding decisions.

On the 14th of May of 2018, Norwegian RHF Order Forum (Beslutningsforum) has released eight new decisions regarding the start of using of new devices and treatment methods.

One of them is the decision regarding usage of the Flash Glucose Monitoring device - Freestyle Libre for the treatment and follow-up of children (less than 18 years) with type 1 diabetes and other types of diabetes.

The Decision Forum recommended Freestyle Libre for introduction in Norway for treatment and following of children with type 1 diabetes and other types of diabetes.

This must be performed in accordance with the negotiations with Abbott Norway. Although, the efficacy of Freestyle Libre is not significantly different in comparison with other finger-pricking methods, however, the using of the sensor and scanner instead of finger stitches will help to simplify everyday life for children.

The full protocol regarding the device can be identified in Norwegian here.

See full details in Norwegian here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.